Region Covered | Injected Dose | Acquisition Time | Number of Beds | Total Scan Time | PSA Level | Reconstruction |
---|---|---|---|---|---|---|
Whole-body | 9.8 mCi of PYLARIFY | 2 min/bed x 3 + 5 min/bed x 5 | 8 | 31 min | 36 ng/ml | TOF Listmode |
1https://www.cancer.org/cancer/prostate-cancer/about/key-statistics
2 Ceci, F., Oprea-Lager, D.E., Emmett, L. et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 48, 1626–1638 (2021).
https://doi.org/10.1007/s00259-021-05245-y
3https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214793s000lbl.pdf
The clinical results, performance and views described in this case study are the experience of the author. Results may vary due to clinical setting, patient presentation and other factors. Many factors could cause the actual results and performance of Canon Medical’s product to be materially different from any of the aforementioned.
© CANON MEDICAL SYSTEMS CORPORATION
© CANON MEDICAL SYSTEMS CORPORATION
The site you see is the Canon Medical Global website. If you choose region / language, we will link to each regional site.